-
Ladies Luncheon Returns to Austin Country Club on September 26 for an “Afternoon in NYC” Benefiting CureDuchenne
Annual Event Features an Afternoon of Fashion and Fun to Raise Funds to Help Find […]
-
cTAP Study Indicates Duchenne Muscular Dystrophy Clinical Trial Enrollment Criteria Should Expand Beyond Ambulatory Status
Study Co-Funded by CureDuchenne and cTAP Highlights Need for More Specific Enrollment Criteria That Could […]
-
In ‘Muscle Memoirs,’ I’ll share tales of life with LGMD
Muscular dystrophy entered my life in the fall of 1984. I was 11 years old […]
-
Finding beauty in how Duchenne has shaped our lives
Duchenne muscular dystrophy (DMD) touches every part of my family’s life. Jason, my husband of […]
-
REGENXBIO ANNOUNCES NEW POSITIVE DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202
Link to press release We are thrilled to share the latest data from RegenXBio’s microdystrophin […]
-
Pfizer stops DMD gene therapy development after trial failure
Pfizer has discontinued development of fordadistrogene movaparvovec, its investigational gene therapy for Duchenne muscular dystrophy […]
-
PepGen Announces Positive Data from Phase 2 Clinical Trial of PGN-EDO51
PepGen Inc. has shared positive clinical data from the first dose cohort (5 mg/kg) of […]
-
Finding Belonging and Fostering Community
While no one asks to be part of this community, and entering the world of […]
-
Duvyzat now available to DMD patients 6 and older in US
Duvyzat (givinostat), a newly approved treatment for Duchenne muscular dystrophy (DMD), is now available in […]
-
Pfizer Discontinues Development of Investigational Mini-Dystrophin Gene Therapy
PPMD is disappointed to learn that Pfizer Inc. has officially discontinued development of the company’s […]
